Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2436-2449

  Rimmerman, Neta ^a   Bradshaw, Heather B ^b   Kozela, Ewa ^c   Levy, Rivka ^a   Juknat, Ana ^c   Vogel, Zvi ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b INDIANA UNIVERSITY   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cannabidiol; Cannabinoid; Caveolin 1; CB 1 receptor; Endocannabinoid; Flotillin 1; Lipid raft; Mass spectrometry; Membrane raft; Microglia

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CAVEOLIN 1; ENDOCANNABINOID; FLOTILLIN 1; N ACYL ETHANOLAMINE; N OLEOYLETHANOLAMINE; N STEAROYLETHANOLAMINE; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DENSITY GRADIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRACELLULAR SIGNALING; LIPID ANALYSIS; LIPID RAFT; MICROGLIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; CANNABIDIOL; CAVEOLIN 1; CELL LINE; ENDOCANNABINOIDS; MEMBRANE MICRODOMAINS; MICE; MICROGLIA; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84859098610     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01380.x     Document Type: Article

References (88)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Bari M, Battista N, Fezza F, Finazzi-Agro A, Maccarrone M (2005a). Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280: 12212-12220.
3. Bari M, Paradisi A, Pasquariello N, Maccarrone M (2005b). Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 81: 275-283. (Pubitemid 41153342)
4. Bari M, Spagnuolo P, Fezza F, Oddi S, Pasquariello N, Finazzi-Agro A et al. (2006). Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. J Immunol 177: 4971-4980. (Pubitemid 44527566)
5. Bari M, Oddi S, De Simone C, Spagnolo P, Gasperi V, Battista N et al. (2008). Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology 54: 45-50. (Pubitemid 350299413)
6. Barnett-Norris J, Lynch D, Reggio PH (2005). Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci 77: 1625-1639. (Pubitemid 41073657)
7. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097. (Pubitemid 27371630)
8. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
9. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. (2001a). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852. (Pubitemid 33016156)
10. Bisogno T, MacCarrone M, De Petrocellis L, Jarrahian A, Finazzi-Agro A, Hillard C et al. (2001b). The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268: 1982-1989. (Pubitemid 32852939)
11. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990). Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27: 229-237. (Pubitemid 20146292)
12. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H (1992). An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31: 616-621.
13. Bradshaw HB, Rimmerman N, Krey JF, Walker JM (2006). Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291: R349-R358. (Pubitemid 44035641)
14. Butovsky E, Juknat A, Elbaz J, Shabat-Simon M, Eilam R, Zangen A et al. (2006). Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas. Mol Cell Neurosci 31: 795-804.
15. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5: e8688.
16. Chini B, Parenti M (2004). G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 32: 325-338. (Pubitemid 38584639)
17. Correa F, Hernangomez-Herrero M, Mestre L, Loria F, Docagne F, Guaza C (2011). The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 25: 736-749.
18. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87. (Pubitemid 26374593)
19. Czarny M, Lavie Y, Fiucci G, Liscovitch M (1999). Localization of phospholipase D in detergent-insoluble, caveolin-rich membrane domains. Modulation by caveolin-1 expression and caveolin-182-101. J Biol Chem 274: 2717-2724. (Pubitemid 29075351)
20. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
21. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B et al. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452. (Pubitemid 32917325)
22. Farooqui AA, Horrocks LA, Farooqui T (2007). Modulation of inflammation in brain: a matter of fat. J Neurochem 101: 577-599. (Pubitemid 46633316)
23. Fay JF, Dunham TD, Farrens DL (2005). Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44: 8757-8769. (Pubitemid 40840441)
24. Fielding CJ, Fielding PE (1997). Intracellular cholesterol transport. J Lipid Res 38: 1503-1521. (Pubitemid 27427648)
25. Fielding PE, Fielding CJ (1995). Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry 34: 14288-14292.
26. Fowler CJ, Jacobsson SO (2002). Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66: 193-200. (Pubitemid 34743594)
27. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003). Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23: 7767-7775. (Pubitemid 37052344)
28. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D (2005). Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48: 1147-1153. (Pubitemid 40725987)
29. Gaus K, Gratton E, Kable EP, Jones AS, Gelissen I, Kritharides L et al. (2003). Visualizing lipid structure and raft domains in living cells with two-photon microscopy. Proc Natl Acad Sci U S A 100: 15554-15559. (Pubitemid 38021028)
30. Godlewski G, Offertaler L, Wagner JA, Kunos G (2009). Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 89: 105-111.
31. Hansen HS (2010). Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224: 48-55.
32. Hermann A, Kaczocha M, Deutsch DG (2006). 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. Aaps J 8: E409-E412. (Pubitemid 43964451)
33. Ignatowska-Jankowska B, Jankowski M, Glac W, Swiergel AH (2009). Cannabidiol-induced lymphopenia does not involve NKT and NK cells. J Physiol Pharmacol 60 (Suppl. 3): 99-103.
34. Ikonen E, Parton RG (2000). Caveolins and cellular cholesterol balance. Traffic 1: 212-217.
35. Jacobsson SO, Fowler CJ (2001). Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132: 1743-1754. (Pubitemid 32397966)
36. Juknat A, Pietr M, Kozela E, Rimmerman N, Levy L, Coppola G et al. (2012). Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and D9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol 165: 2512-2528.
37. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG (2006). Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase. J Biol Chem 281: 9066-9075. (Pubitemid 43864619)
38. Kaczocha M, Glaser ST, Deutsch DG (2009). Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A 106: 6375-6380.
39. Keren O, Sarne Y (2003). Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res 980: 197-205. (Pubitemid 36829439)
40. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z (2010). Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285: 1616-1626.
41. Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R et al. (2011). Cannabidiol inhibits pathogenic T-cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol 163: 1507-1519.
42. Lajoie P, Nabi IR (2010). Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol 282: 135-163.
43. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q et al. (2006). A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 103: 13345-13350. (Pubitemid 44380110)
44. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005a). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19. (Pubitemid 40069962)
45. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D (2005b). Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 62: 708-716.
46. Luo DX, Cao DL, Xiong Y, Peng XH, Liao DF (2010). A novel model of cholesterol efflux from lipid-loaded cells. Acta Pharmacol Sin 31: 1243-1257.
47. Maccarrone M, Pauselli R, Di Rienzo M, Finazzi-Agro A (2002). Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J 366: 137-144. (Pubitemid 34971812)
48. Maccarrone M, De Chiara V, Gasperi V, Viscomi MT, Rossi S, Oddi S et al. (2009). Lipid rafts regulate 2-arachidonoylglycerol metabolism and physiological activity in the striatum. J Neurochem 109: 371-381.
49. Maccarrone M, Dainese E, Oddi S (2010). Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35: 601-608.
50. Macdonald JL, Pike LJ (2005). A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res 46: 1061-1067.
51. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J et al. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
52. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E et al. (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104: 1091-1100. (Pubitemid 351143654)
53. McFarland MJ, Barker EL (2005). Lipid rafts: a nexus for endocannabinoid signaling? Life Sci 77: 1640-1650. (Pubitemid 41073658)
54. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker EL (2004). A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J Biol Chem 279: 41991-41997. (Pubitemid 39313650)
55. McFarland MJ, Bardell TK, Yates ML, Placzek EA, Barker EL (2008). RNA interference-mediated knockdown of dynamin 2 reduces endocannabinoid uptake into neuronal dCAD cells. Mol Pharmacol 74: 101-108. (Pubitemid 351872163)
56. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM et al. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
57. Moffett S, Brown DA, Linder ME (2000). Lipid-dependent targeting of G proteins into rafts. J Biol Chem 275: 2191-2198. (Pubitemid 30060849)
58. Muccioli GG, Stella N (2008). Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 54: 16-22. (Pubitemid 350299394)
59. Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM et al. (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 27: 2883-2889. (Pubitemid 46438968)
60. Mukhopadhyay S, Cowsik SM, Lynn AM, Welsh WJ, Howlett AC (1999). Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. Biochemistry 38: 3447-3455.
61. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K (1995). VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 92: 10339-10343.
62. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
63. Oddi S, Spagnuolo P, Bari M, D'Agostino A, Maccarrone M (2007). Differential modulation of type 1 and type 2 cannabinoid receptors along the neuroimmune axis. Int Rev Neurobiol 82: 327-337.
64. Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E et al. (2008). Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci 65: 840-850.
65. Oddi S, Fezza F, Pasquariello N, D'Agostino A, Catanzaro G, De Simone C et al. (2009). Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem Biol 16: 624-632.
66. Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA (2001). Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem 276: 42063-42069.
67. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
68. Overton HA, Fyfe MC, Reynet C (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153 (Suppl. 1): S76-S81. (Pubitemid 351340991)
69. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N et al. (2009). Differential changes in GPR55 during microglial cell activation. FEBS Lett 583: 2071-2076.
70. Pike LJ (2006). Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 47: 1597-1598.
71. Pike LJ, Han X, Chung KN, Gross RW (2002). Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 41: 2075-2088. (Pubitemid 34132282)
72. Placzek EA, Okamoto Y, Ueda N, Barker EL (2008). Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2- arachidonylglycerol. J Neurochem 107: 987-1000.
73. Rakhshan F, Day TA, Blakely RD, Barker EL (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960-967. (Pubitemid 30136588)
74. Rimmerman N, Hughes HV, Bradshaw HB, Pazos MX, Mackie K, Prieto AL et al. (2008). Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. Br J Pharmacol 153: 380-389.
75. Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw HB, Vogel Z (2011). The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell Mol Neurobiol DOI: 10.1007/s10571-011-9692-3 [Epub ahead of print].
76. Ruiz-Valdepenas L, Martinez-Orgado JA, Benito C, Millan A, Tolon RM, Romero J (2011). Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J Neuroinflammation 8: 5.
77. Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C et al. (2005). Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579: 6343-6349. (Pubitemid 41612150)
78. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C et al. (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 70: 1298-1306. (Pubitemid 44435982)
79. Sharma DK, Choudhury A, Singh RD, Wheatley CL, Marks DL, Pagano RE (2003). Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling. J Biol Chem 278: 7564-7572. (Pubitemid 36800764)
80. Song SK, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP (1996). Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free. Purification of caveolae microdomains. J Biol Chem 271: 9690-9697.
81. Stella N (2009). Endocannabinoid signaling in microglial cells. Neuropharmacology 56 (Suppl. 1): 244-253.
82. Stella N (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030.
83. Thors L, Alajakku K, Fowler CJ (2007). The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol 150: 951-960. (Pubitemid 46536631)
84. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996). Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19: 1109-1111. (Pubitemid 26303382)
85. Wilson BS, Steinberg SL, Liederman K, Pfeiffer JR, Surviladze Z, Zhang J et al. (2004). Markers for detergent-resistant lipid rafts occupy distinct and dynamic domains in native membranes. Mol Biol Cell 15: 2580-2592. (Pubitemid 38691849)
86. Xie XQ, Chen JZ (2005). NMR structural comparison of the cytoplasmic juxtamembrane domains of G-protein-coupled CB1 and CB2 receptors in membrane mimetic dodecylphosphocholine micelles. J Biol Chem 280: 3605-3612.
87. Yates ML, Barker EL (2009). Organized trafficking of anandamide and related lipids. Vitam Horm 81: 25-53.
88. Zhai J, Strom AL, Kilty R, Venkatakrishnan P, White J, Everson WV et al. (2009). Proteomic characterization of lipid raft proteins in amyotrophic lateral sclerosis mouse spinal cord. FEBS J 276: 3308-3323.